Drug-induced heart failure

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1152-1162

  Feenstra, Johannes ^a   Grobbee, Diederick E ^b   Remme, Willem J ^c   Stacker, Bruno H Ch ^b,d  

^a Inspectorate for Health Care   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DILTIAZEM; DNA POLYMERASE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN RADICAL; PACLITAXEL; RNA POLYMERASE;

CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; HEART VENTRICLE FUNCTION; HUMAN; INOTROPISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033117024     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00006-6     Document Type: Article

References (133)

1. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741-51.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7.
3. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;72(Suppl 2):S3-9.
4. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25.
5. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991;121:1852-3.
6. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Heart J 1993;70:499-502.
7. Camaggi CM, Comparsi R, Strocchi E, et al. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 1988;21:221-8.
8. Fu LX, Waagstein F, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990;29:15-20.
9. 2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol 1991;36:217-8.
10. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
11. Bu'Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993;70:185-8.
12. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
13. Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987;106:814-6.
14. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984;3:71-6.
15. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
16. Carrio I, Estorch M, Lopez-Pousa A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 1996;23:359-64.
17. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
18. Manthorpe R, Svensson O. Cardiomyopathy following intravenous cyclophosphamide therapy in a patient with Wegener's granulomatosis (letter). Clin Exp Rheumatol 1996;14:702-3.
19. Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-23.
20. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
21. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
22. Jekunen A, Heikkila P, Maiche A, Pyrhonen S. Paclitaxel-induced myocardial damage detected by electron microscopy (letter). Lancet 1994;343:727-8.
23. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
24. Mather FJ, Simon RM, Clark GM, Von Hoff DD. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987;71:609-13.
25. Cassidy J, Merrick MV, Smyth JF, Leonard RC. Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography. Eur J Cancer Clin Oncol 1988;24:935-8.
26. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993;33:1060-70.
27. Akhtar SS, Wani BA, Bano ZA, et al. 5-Fluorouracil-induced severe but reversible cardiogenic shock: a case report. Tumori 1996;82:505-7.
28. Chaudary S, Song SY, Jaski BE. Profound, yet reversible, heart failure secondary to 5-fluorouracil. Am J Med 1988;85:454-6.
29. Coronel B, Madonna O, Mercatello A, et al. Myocardiotoxicity of 5 fluorouracil. Intensive Care Med 1988;14:429-30.
30. Rahimtoola SH. The hibernating myocardium in ischaemia and congestive heart failure. Eur Heart J 1993;14:22-6.
31. Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72:2242-7.
32. Conrad ME. Cytarabine and cardiac failure (letter). Am J Hematol 1992;41:143-4.
33. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
34. McNeil C. Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst 1998;90:882-3.
35. Schlepper M. Cardiodepressive effects of antiarrhythmic drugs. Eur Heart J 1989;10 Suppl E:73-80.
36. Hammermeister KE. Adverse hemodynamic effects of antiarrhythmic drugs in congestive heart failure. Circulation 1990;81:1151-3.
37. Pharand C, Kluger J, O'Rangers E, et al. Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clin Pharmacol Ther 1995;57:471-8.
38. Greene HL, Richardson DW, Hallstrom AP, et al. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:393-8.
39. Gottlieb SS, Packer M. Deleterious hemodynamic effects of lidocaine in severe congestive heart failure. Am Heart J 1989;118:611-2.
40. Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 1991;68:1025-31.
41. Pratt CM, Podrid PJ, Seals AA, et al. Effects of Ethmozine (moricizine HC1) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments. Am J Cardiol 1987;60:73F-8F.
42. Dukes MNG. Meyler's Side Effects of Drugs, 14th ed. Amsterdam: Elsevier Science Bv, 1996.
43. Maloney JD, Nissen RG, McColgan JM. Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents. Am Heart J 1980;100:1023-30.
44. Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3A-9A.
45. Schulze JJ, Knops J. Effects of flecainide on contractile force and electrophysiological parameters in cardiac muscle. Arzeimittelforschung 1982;32:1025-9.
46. Gottlieb SS, Kukin ML, Median N, et al. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 1990;81:860-4.
47. Ball S. Congestive heart failure from betaxolol. Case report. Arch Ophthalmol 1987;105:320.
48. Linkewich JA, Herling IM. Bradycardia and congestive heart failure associated with ocular timolol maleate. Am J Hosp Pharm 1981;38:699-701.
49. Britman NA. Cardiac effects of topical timolol (letter). N Engl J Med 1979;300:566.
50. Atkins JM, Pugh BR Jr, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol 1985;99:173-5.
51. Bauer K, Brunner-Ferber F, Distlerath LM, et al. Assessment of systemic effects of different ophthalmic beta-blockers in healthy volunteers. Clin Pharmacol Ther 1991;49:658-64.
52. Berlin I, Marcel P, Uzzan B, et al. A single dose of three different ophthalmic beta-blockers antagonizes the chronotropic effect of isoproterenol in healthy volunteers. Clin Pharmacol Ther 1987;41:622-6.
53. Mekki QA, Penhall R, Edgar DF, et al. Local and systemic effects of pindolol eye drops. Br J Clin Pharmacol 1983;15:112-3.
54. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88:736-8.
55. Monane M, Bohn RL, Gurwitz JH, et al. Topical glaucoma medications and cardiovascular risk in the elderly. Clin Pharmacol Ther 1994;55:76-83.
56. Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
57. ver Donck L, Wouters L, Olbrich HG, et al. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol 1991;18:1-3.
58. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
59. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
60. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
61. Tashima CK, Rose M. Pulmonary edema and salicylates (letter). Ann Intern Med 1974;81:274-5.
62. Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977;237:1716-7.
63. Nevins M, Berque S, Corwin N, Lyon L. Phenylbutazone and pulmonary oedema. Lancet 1969;2:1358.
64. Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979;91:47-9.
65. Laiwah AC, Mactier RA. Antagonistic effect of nonsteroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure. Br Med J 1981;283:714.
66. Van den Ouweland FA, Gribnau FW, Meyboom RH. Congestive heart failure due to nonsteroidal antiinflammatory drugs in the elderly. Age Ageing 1988;17:8-16.
67. Simon LS, Mills JA. Drug therapy: nonsteroidal antiinflammatory drugs. N Engl J Med 1980;302:1179-85.
68. Sturrock ND, Struthers AD. Non-steroidal antiinflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function. Br J Clin Pharmacol 1993;35:343-8.
69. Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985;30:427-43.
70. Koopmans PP. Pathophysiological and clinical aspects of the interaction between non-steroidal anti-inflammatory drugs (NSAID) and diuretics. Neth J Med 1985;28:524-9.
71. Carmichael J, Shankel SW. Effects of nonsteroidal antiinflammatory drugs on prostaglandins and renal function. Am J Med 1985;78:992-1000.
72. Schlondorff D. Renal complications of nonsteroidal antiinflammatory drugs. Kidney Int 1993;44:643-53.
73. Feenstra J, Grobbee DE, Mosterd A, Stricker BHC. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Safety 1997;17:166-80.
74. Sedor JR, Davidson EW, Dunn MJ. Effects of nonsteroidal anti-inflammatory drugs in healthy subjects. Am J Med 1986;81:58-70.
75. Bunning RD, Barth WF. Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA 1982;248:2864-7.
76. Aronoff GR. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992;19 Suppl 36:25-31.
77. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:1-9.
78. Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles. Fact or fiction? Drug Safety 1994;10:183-95.
79. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
80. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80 Suppl 6:IV59-67.
81. Chew CY, Hecht HS, Collett JT, et al. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 1981;47:917-22.
82. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993;104:618-20.
83. Francis GS. Calcium channel blockers and congestive heart failure. Circulation 1991;83:336-8.
84. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60.
85. Ferrari R. Major differences among the three classes of calcium antagonists. Eur Heart J 1997;18 Suppl A:A56-70.
86. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.
87. Packer M, CM OC, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-14.
88. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856-63.
89. Shimosato S, Iwatsuki N, Carter JG. Cardio-circulatory effects of enflurane anesthesia in health and disease. Acta Anaesthesiol Scand Suppl 1979;71:69-70.
90. Schmidt U, Schwinger RH, Bohm S, et al. Evidence for an interaction of halothane with the L-type Ca2+ channel in human myocardium. Anesthesiology 1993;79:332-9.
91. Rifat K. Effets cardiovasculaires de l'enflurane. Med Hyg 1979;37:3602.
92. McKinney MS, Fee JP, Clarke RS. Cardiovascular effects of isoflurane and halothane in young and elderly adult patients. Br J Anaesth 1993;71:696-701.
93. Becker KE Jr, Tonnesen AS. Cardiovascular effects of plasma levels of thiopental necessary for anesthesia. Anesthesiology 1978;49:197-200.
94. Searle NR, Sahab P. Propofol in patients with cardiac disease. Can J Anaesth 1993;40:730-47.
95. Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. Br Med J 1992;305:613-6.
96. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10:115-50.
97. Sonnenblick M, Rosin A. Cardiotoxicity of Interferon. A review of 44 cases. Chest 1991;99:557-61.
98. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by Interferon. Br Med J 1990;300:1174-5.
99. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988;85:549-51.
100. Deyton LR, Walker RE, Kovacs JA, et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989;321:1246-9.
101. Sartori M, Andorno S, La Terra G, et al. Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur J Clin Invest 1995;25:68-70.
102. Todd PA, Goa KL. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 1992;43:111-22.
103. Goel M, Flaherty L, Lavine S, Redman BG. Reversible cardiomyopathy after high-dose interleukin-2 therapy. J Immunother 1992;11:225-9.
104. Fragasso G, Tresoldi M, Benti R, et al. Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer. Br Heart J 1994;71:166-9.
105. Schuchter LM, Hendricks CB, Holland KH, et al. Eosinophilic myocarditis associated with high-dose interleukin-2 therapy. Am J Med 1990;88:439-40.
106. Glassman AH, Bigger JT Jr, Giardina EV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979;1:468-72.
107. Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 1981;38:815-20.
108. Roos JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol 1983;15 Suppl 3:439S-4SS.
109. Jefferson JW. Cardiovascular effects and toxicity of anxiolytics and antidepressants. J Clin Psychiatry 1989;50:368-78.
110. Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure (letter). Am J Psychiatry 1991;148:1601.
111. Lucas CM, Cheriex EC, van der Veen FH, et al. Imipramine induced heart failure in the dog: a model to study the effect of cardiac assist devices. Cardiovasc Res 1992;26:804-9.
112. Raeder EA, Burckhardt D, Neubauer H, et al. Long-term tri- and tetra-cyclic antidepressants, myocardial contractility, and cardiac rhythm. Br Med J 1978;2:666-7.
113. Burckhardt D, Raeder E, Muller V, et al. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978;239:213-6.
114. Giardina EG, Johnson LL, Vita J, et al. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. Am Heart J 1985;109:992-8.
115. Veith RC, Raskind MA, Caldwell JH, et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982;306:954-9.
116. Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983;250:1997-2001.
117. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997;102:54-9.
118. Spier SA, Frontera MA. Unexpected deaths in depressed medical inpatients treated with fluoxetine. J Clin Psychiatry 1991;52:377-82.
119. Hale AS. New antidepressants: use in high-risk patients. J Clin Psychiatry 1993;54 Suppl 8:61-70 (discussion 71-3).
120. Weidle PJ, Vlasses PH. Systemic hypertension associated with cyclosporine: a review. Drug Intell Clin Pharm 1988;22:443-51.
121. Aabo J, De Coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect (letter). Lancet 1987;2:637-8.
122. Granberry MC, White LM, Gardner SF. Exacerbation of congestive heart failure after administration of polyethylene glycol-electrolyte lavage solution. Ann Pharmacother 1995;29:1232-5.
123. Johansson SA. Acute right heart failure during treatment with epsilon amino caproic acid (E-ACA). Acta Med Scand 1967;182:331-4.
124. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992;69:108G-18G.
125. Vale JA, Maclean KS. Amantadine-induced heart failure. Lancet 1977;1:548.
126. Brown DL, Sather S, Cheitlin MD. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 1993;125:1439-41.
127. Tchekmedyian NS, Tait N, Aisner J. High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Semin Oncol 1986;13 Suppl 4:20-5.
128. Oken DE, Renal and extrarenal considerations in high-dose mannitol therapy. Ren Fail 1994;16:147-59.
129. Berdoukas V, Bentley P, Frost H, Schnebli HP. Toxicity of oral iron chelator LI (letter). Lancet 1993;341:1088.
130. Cowan RE, Wright JT. Dapsone and severe hypoalbuminaemia in dermatitis herpetiformis. Br J Dermatol 1981;104:201-4.
131. Miura DS, Keren G, Torres V, et al. Antiarrhythmic effects of cibenzoline. Am Heart J 1985;109:827-33.
132. White JL, Fleming NW, Burke TA, et al. Pulmonary edema after PGE1 infusion. J Cardiothorac Anesth 1990;4:744-7.
133. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31-6.